Table 3. Randomized Phase III Immunotherapy Trials
Trial
Na onal clinical
trial iden fier Status
a
PSA-TRICOM ± GM-CSF in
mCPRC
NCT01322490 Ac ve, not recrui ng; Expected
comple on date June 2018
± DCVAC added to docetaxel
and prednisone in mCRPC
NCT02111577 Recrui ng; Expected comple on
date June 2019
Valcyclovir ± ProstAtak®
as adjuvant to up-front
radia on in localized
pa ents
NCT01436968 Recrui ng; Expected comple on
date December 2020
a
As determined by ClinicalTrials.gov. Accessed July 27, 2017
Table 2. Phase II Sipuleucel-T Combina on Studies (cont'd)
Trial
Na onal clinical
trial iden fier Status
a
A study of
sipuleucel-T with
administra on of
enzalutamide
NCT01981122
Ac ve, not recrui ng; Expected comple on
date July 2017
Sipuleucel-T +
indoximod
NCT01560923 Ac ve, not recrui ng; Expected comple on
date November 2017
Sipuleucel-T
± RT
NCT01807065 Ac ve, not recrui ng; Expected comple on
date January 2018
Sipuleucel-T ±
pTVG-HP DNA
booster vaccine
NCT01706458 Ac ve, not recrui ng; Expected comple on
date July 2021
Sipuleucel-T ±
ipilimumab
NCT01804465 Recrui ng; Expected comple on date
December 2019
Sipuleucel-T ±
radium-223
NCT02463799 Recrui ng; Expected comple on date
December 2020
a
As determined by ClinicalTrials.gov. Accessed June 15, 2017
